3 active not recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Melanoma Recurrent: new trials by email Literature Review of Melanoma Recurrent trials Research Report on Melanoma Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution) - Melanoma Metastatic, Melanoma of Skin | Phase 1 / Phase 2 | Active not recruiting | BioInvent International AB | 35 | 2024-12-11 | 2026-10-02 |
| Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) Pembrolizumab - Melanoma Metastatic, Melanoma Recurrent | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 29 | 2021-12-10 | 2026-01-29 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors ST101, Temozolomide, Radiation - Glioblastoma, Melanoma Stage IV | Phase 1 / Phase 2 | Active not recruiting | Sapience Therapeutics | 125 | 2020-07-01 | 2026-02-09 |
Melanoma (3) · Brain Neoplasms (1) · Breast Neoplasms (1) · Glioblastoma (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Uveal Melanoma (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Skin Diseases (3) · Skin Neoplasms (3) · Skin and Connective Tissue Diseases (3) · Astrocytoma (1) · Brain Diseases (1) · Breast Diseases (1) · Central Nervous System Diseases (1)
pembrolizumab (2) · Ipilimumab (1) · Radiation (1) · Solutions (1) · Temozolomide (1)
BioInvent International AB (1) · Instituto do Cancer do Estado de São Paulo (1) · Sapience Therapeutics (1)
United Kingdom (2) · Brazil (1) · Germany (1) · Spain (1) · United States (1)